Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640334 | 0.87 | MAPT (0.54) | CCNA2CDK2GRM4MAPTTSHR | |
| SCHEMBL16640332 | 0.81 | MAPT (0.49) | CCNA2CDK2GRM4MAPTTSHR | |
| SCHEMBL16640331 | 0.81 | USP2 (0.43) | CCNA2CDK2GRM4MAPTTSHR | |
| SCHEMBL16640342 | 0.81 | CDK4 (0.41) | CCNA2CDK2GRM4MAPTTSHR | |
| SCHEMBL8229406 | 0.77 | ALDH1A1 (0.50) | CCNA2CDK2GRM4TSHRHPGD | |
| SCHEMBL25467584 | 0.76 | DDB1 (0.46) | CCNA2CDK2GRM4MAPTTSHR | |
| SCHEMBL28794020 | 0.76 | CCNA2 (0.43) | CCNA2CDK2GRM4L3MBTL1HPGD | |
| SCHEMBL24835424 | 0.76 | MAPT (0.36) | CCNA2CDK2GRM4MAPTTSHR | |
| SCHEMBL22017688 | 0.75 | FEN1 (0.65) | CCNA2CDK2GRM4L3MBTL1FEN1 | |
| SCHEMBL1609990 | 0.75 | FEN1 (0.56) | GRM4MAPTL3MBTL1NPC1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11189808-B2 | Platinum complexes and devices | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200152891-A1 | PLATINUM COMPLEXES AND DEVICES | UNIV ARIZONA STATE (US) | 2020-05-14 | — | — | US | disclosed |
| US-9947881-B2 | Platinum complexes and devices | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170012224-A1 | PLATINUM COMPLEXES AND DEVICES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-01-12 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-9385329-B2 | Platinum complexes and devices | Arizona Board of Regents on behalf of Arizona State University and Universal Display Corporation (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105556-A1 | PLATINUM COMPLEXES AND DEVICES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11189808-B2 | Platinum complexes and devices | OXA1L, OCIAD1, OCIAD2 | CCNA2 1810/4885CDK2 1819/4885GRM4 3031/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | CCNA2 98/4885CDK2 38/4885GRM4 4501/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | CCNA2 1577/4885CDK2 1069/4885GRM4 2092/4885 |
| US-20200152891-A1 | PLATINUM COMPLEXES AND DEVICES | OXA1L, OCIAD1, OCIAD2 | CCNA2 1810/4885CDK2 1819/4885GRM4 3031/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CCNA2 4093/4885CDK2 1171/4885GRM4 2734/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CCNA2 524/4885CDK2 1412/4885GRM4 4690/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | CCNA2 2171/4885CDK2 1666/4885GRM4 3969/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CCNA2 656/4885CDK2 152/4885GRM4 3988/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CCNA2 4093/4885CDK2 1171/4885GRM4 2734/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | CCNA2 524/4885CDK2 1412/4885GRM4 4690/4885 |
| US-20170012224-A1 | PLATINUM COMPLEXES AND DEVICES | OXA1L, OCIAD1, OCIAD2 | CCNA2 1810/4885CDK2 1819/4885GRM4 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.